Your browser doesn't support javascript.
loading
FLI and FIB-4 in diagnosing metabolic dysfunction-associated steatotic liver disease in primary care: High prevalence and risk of significant disease.
Álvares-da-Silva, Mário Reis; Vargas, Márcia da Silva; Rabie, Soheyla Mohd Souza; Jonko, Gabriella; Riedel, Patricia Gabriela; Longo, Larisse; Gonçalves, Marcelo Rodrigues; Luft, Vivian Cristine; Joveleviths, Dvora.
Afiliação
  • Álvares-da-Silva MR; Graduate Program in Gastroenterology and Hepatology, School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, 90035-007, Rio Grande do Sul, Brazil; Experimental Laboratory in Hepatology and Gastroenterology, Hospital de Clinicas de Porto Alegre (HCPA), Porto Alegre, 90035
  • Vargas MDS; Graduate Program in Gastroenterology and Hepatology, School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, 90035-007, Rio Grande do Sul, Brazil; Nutrition Unit, HCPA, Porto Alegre, 90035-007, Rio Grande do Sul, Brazil.
  • Rabie SMS; Graduate Program in Gastroenterology and Hepatology, School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, 90035-007, Rio Grande do Sul, Brazil; Nutrition Unit, HCPA, Porto Alegre, 90035-007, Rio Grande do Sul, Brazil.
  • Jonko G; Graduate Program in Gastroenterology and Hepatology, School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, 90035-007, Rio Grande do Sul, Brazil.
  • Riedel PG; Graduate Program in Gastroenterology and Hepatology, School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, 90035-007, Rio Grande do Sul, Brazil.
  • Longo L; Graduate Program in Gastroenterology and Hepatology, School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, 90035-007, Rio Grande do Sul, Brazil; Experimental Laboratory in Hepatology and Gastroenterology, Hospital de Clinicas de Porto Alegre (HCPA), Porto Alegre, 90035
  • Gonçalves MR; Department of Social Medicine, UFRGS, Porto Alegre, 90035-003, Rio Grande do Sul, Brazil; Department of Nutrition, School of Medicine, UFRGS, Porto Alegre, 90050-170, Rio Grande do Sul, Brazil; Graduate Program in Food, Nutrition and Health, School of Medicine, UFRGS, Porto Alegre, 90035-007, Rio Gr
  • Luft VC; Department of Social Medicine, UFRGS, Porto Alegre, 90035-003, Rio Grande do Sul, Brazil; Department of Nutrition, School of Medicine, UFRGS, Porto Alegre, 90050-170, Rio Grande do Sul, Brazil; Graduate Program in Epidemiology, School of Medicine, UFRGS, Porto Alegre, 90035-003, Rio Grande do Sul, B
  • Joveleviths D; Graduate Program in Gastroenterology and Hepatology, School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, 90035-007, Rio Grande do Sul, Brazil; Experimental Laboratory in Hepatology and Gastroenterology, Hospital de Clinicas de Porto Alegre (HCPA), Porto Alegre, 90035
Ann Hepatol ; : 101584, 2024 Oct 11.
Article em En | MEDLINE | ID: mdl-39395769
ABSTRACT
INTRODUCTION AND

OBJECTIVES:

Public health policies in metabolic dysfunction-associated steatotic liver disease (MASLD) are still lacking. This study aims to estimate the prevalence and severity of MASLD in primary health care (PHC) through non-invasive markers. PATIENTS AND

METHODS:

Two-phase study, including a retrospective (RETR) and a prospective (PROS) one, was carried out in PHC in Brazil. In RETR, metabolic and hepatic profiles of 12,054 patients, including FIB-4, were evaluated. In PROS, 350 patients were randomly selected and submitted to a clinical and nutritional assessment.

RESULTS:

RETR (65.4 % women, mean age 55.3 years old) dyslipidemia, hypertension, and type 2 diabetes mellitus (T2DM) present in 40.8 %, 34.3 %, and 12.2 % of the electronic health records, respectively. Fasting glucose >100 mg/dL in 34.5 %, and glycated hemoglobin higher than 5.7 % in 51.5 %, total cholesterol >200 mg/dL and triglycerides >150 mg/dL in 40.8 % and 32.1 %, respectively. Median FIB-4 was of 1.33, 5 % >2.67. No one had MASLD as a diagnostic hypothesis; PROS(71.8 % women, mean age 58 years old) body mass index (BMI) ≥30 kg/m² in 31.8 %. MASLD prevalence (FLI≥ 30 + cardiometabolic features) of 62.1 %; 39.4 % of patients had FLI ≥60, with higher BMI, waist circumference, fasting glucose, triglycerides, AST, ALT and GGT, as well as lower HDL-cholesterol (p < 0.001). FIB-4>1.3 in 40 % and NAFLD Fibrosis Score (NFS)>-1.45 in 59.2 % of steatotic patients.

CONCLUSIONS:

There is a high prevalence of MASLD in PHC, with a significant risk of liver fibrosis. These findings reinforce we need to develop public policies to defeat MASLD epidemics.
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Ann Hepatol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2024 Tipo de documento: Article País de publicação: México
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Ann Hepatol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2024 Tipo de documento: Article País de publicação: México